SFI
BCAB icon

Susquehanna Fundamental Investments’s BioAtla BCAB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,156
Closed -$289K – 655
2023
Q1 		$289K Hold
2,156
– – 0.01% 795
2022
Q4 		$889K Hold
2,156
– – 0.02% 684
2022
Q3 		$830K Buy
+2,156
New +$706K 0.01% 860

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's BCAB Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of BioAtla (BCAB) in Q2 2023, closing a stake of 2,156 shares — an estimated $289K sold.

Susquehanna Fundamental Investments first reported a position in BCAB in Q3 2022 and held it in 3 quarters. The position peaked at $889K in Q4 2022. 87 funds tracked by Wall St. Rank hold BCAB as of Q2 2023.

  • Susquehanna Fundamental Investments reported no remaining BioAtla position as of Q2 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 2,156 BioAtla shares in Q2 2023, an estimated $289K.
  • Susquehanna Fundamental Investments first reported a position in BioAtla in Q3 2022 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's BioAtla position peaked at $889K in Q4 2022.
  • 87 funds tracked by Wall St. Rank held BioAtla as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.